Direkt zum Inhalt
Merck

Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling.

The Journal of experimental medicine (2020-07-30)
Alice Lepelley, Maria José Martin-Niclós, Melvin Le Bihan, Joseph A Marsh, Carolina Uggenti, Gillian I Rice, Vincent Bondet, Darragh Duffy, Jonny Hertzog, Jan Rehwinkel, Serge Amselem, Siham Boulisfane-El Khalifi, Mary Brennan, Edwin Carter, Lucienne Chatenoud, Stéphanie Chhun, Aurore Coulomb l'Hermine, Marine Depp, Marie Legendre, Karen J Mackenzie, Jonathan Marey, Catherine McDougall, Kathryn J McKenzie, Thierry Jo Molina, Bénédicte Neven, Luis Seabra, Caroline Thumerelle, Marie Wislez, Nadia Nathan, Nicolas Manel, Yanick J Crow, Marie-Louise Frémond
ZUSAMMENFASSUNG

Heterozygous missense mutations in coatomer protein subunit α, COPA, cause a syndrome overlapping clinically with type I IFN-mediated disease due to gain-of-function in STING, a key adaptor of IFN signaling. Recently, increased levels of IFN-stimulated genes (ISGs) were described in COPA syndrome. However, the link between COPA mutations and IFN signaling is unknown. We observed elevated levels of ISGs and IFN-α in blood of symptomatic COPA patients. In vitro, both overexpression of mutant COPA and silencing of COPA induced STING-dependent IFN signaling. We detected an interaction between COPA and STING, and mutant COPA was associated with an accumulation of ER-resident STING at the Golgi. Given the known role of the coatomer protein complex I, we speculate that loss of COPA function leads to enhanced type I IFN signaling due to a failure of Golgi-to-ER STING retrieval. These data highlight the importance of the ER-Golgi axis in the control of autoinflammation and inform therapeutic strategies in COPA syndrome.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Monoklonaler ANTI-FLAG® M2-Antikörper in Maus hergestellte Antikörper, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
Sigma-Aldrich
Ziegenserum
Sigma-Aldrich
Saponin Quillaja sp., Sapogenin content 20-35 %
Sigma-Aldrich
MISSION® pLKO.1-puro Non-Target shRNA Control Plasmid DNA, Targets no known genes from any species
Sigma-Aldrich
MISSION® esiRNA, targeting human STIM1
Sigma-Aldrich
MISSION® esiRNA, targeting human COPA